Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity—such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)—most Americans wouldn’t take them, according to a September 2024 survey of U.S. adults. Hover over the chart below to explore respondents’ views on weight loss methods.
N = 2,221; data collected Sept. 5 2024